Lutetium Lu 177 Rosopatamab Tetraxetan

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.

**Synonyms:** - 177Lu-DOTA-TLX591 - DOTA-HUJ-591 LU-177 - Lu 177 MOAB J591 - Lutetium Lu 177 Monoclonal Antibody J591 - Lutetium Lu 177 Rosopatamab - Lutetium Lu 177-DOTA-Rosopatamab - Lutetium Lu 177-DOTA-TLX591 - ROSOPATAMAB TETRAXETAN LUTETIUM LU-177